Literature DB >> 25707943

Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy.

Matthew S Stratton1, Timothy A McKinsey.   

Abstract

Acetylation of lysine residues within nucleosomal histone tails provides a crucial mechanism for epigenetic control of gene expression. Acetyl groups are coupled to lysine residues by histone acetyltransferases (HATs) and removed by histone deacetylases (HDACs), which are also commonly referred to as "writers" and "erasers", respectively. In addition to altering the electrostatic properties of histones, lysine acetylation often creates docking sites for bromodomain-containing "reader" proteins. This review focuses on epigenetic control of pulmonary hypertension (PH) and associated right ventricular (RV) cardiac hypertrophy and failure. Effects of small molecule HDAC inhibitors in pre-clinical models of PH are highlighted. Furthermore, we describe the recently discovered role of bromodomain and extraterminal (BET) reader proteins in the control of cardiac hypertrophy, and provide evidence suggesting that one member of this family, BRD4, contributes to the pathogenesis of RV failure. Together, the data suggest intriguing potential for pharmacological epigenetic therapies for the treatment of PH and right-sided heart failure.

Entities:  

Keywords:  HDAC; RV hypertrophy; bromodomain; bromodomaine; epigenetics; hypertension pulmonaire; hypertrophie ventriculaire droite; pulmonary hypertension; épigénétique

Mesh:

Substances:

Year:  2014        PMID: 25707943      PMCID: PMC4975937          DOI: 10.1139/bcb-2014-0119

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  93 in total

Review 1.  An update on medical therapy for pulmonary arterial hypertension.

Authors:  Yan Wu; Dermot S O'Callaghan; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

2.  Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.

Authors:  Young Kuk Cho; Gwang Hyeon Eom; Hae Jin Kee; Hyung-Seok Kim; Woo-Yeon Choi; Kwang-Il Nam; Jae Sook Ma; Hyun Kook
Journal:  Circ J       Date:  2010-03-06       Impact factor: 2.993

3.  Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.

Authors:  Douglas D Lemon; Todd R Horn; Maria A Cavasin; Mark Y Jeong; Kurt W Haubold; Carlin S Long; David C Irwin; Sylvia A McCune; Eunhee Chung; Leslie A Leinwand; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

4.  HDAC4 deacetylase associates with and represses the MEF2 transcription factor.

Authors:  E A Miska; C Karlsson; E Langley; S J Nielsen; J Pines; T Kouzarides
Journal:  EMBO J       Date:  1999-09-15       Impact factor: 11.598

Review 5.  Histone deacetylases: anti-angiogenic targets in cancer therapy.

Authors:  Denis Mottet; Vincent Castronovo
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

Review 6.  HDAC-dependent ventricular remodeling.

Authors:  Min Xie; Joseph A Hill
Journal:  Trends Cardiovasc Med       Date:  2013-03-15       Impact factor: 6.677

7.  Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.

Authors:  Mercedes Lobera; Kevin P Madauss; Denise T Pohlhaus; Quentin G Wright; Mark Trocha; Darby R Schmidt; Erkan Baloglu; Ryan P Trump; Martha S Head; Glenn A Hofmann; Monique Murray-Thompson; Benjamin Schwartz; Subhas Chakravorty; Zining Wu; Palwinder K Mander; Laurens Kruidenier; Robert A Reid; William Burkhart; Brandon J Turunen; James X Rong; Craig Wagner; Mary B Moyer; Carrow Wells; Xuan Hong; John T Moore; Jon D Williams; Dulce Soler; Shomir Ghosh; Michael A Nolan
Journal:  Nat Chem Biol       Date:  2013-03-24       Impact factor: 15.040

8.  Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.

Authors:  Sarah M Williams; Lucy Golden-Mason; Bradley S Ferguson; Katherine B Schuetze; Maria A Cavasin; Kim Demos-Davies; Michael E Yeager; Kurt R Stenmark; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2013-12-26       Impact factor: 5.000

Review 9.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

10.  The right ventricle: biologic insights and response to disease.

Authors:  Lori A Walker; Peter M Buttrick
Journal:  Curr Cardiol Rev       Date:  2009-01
View more
  9 in total

1.  Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.

Authors:  Feng Chen; Xueyi Li; Emily Aquadro; Stephen Haigh; Jiliang Zhou; David W Stepp; Neal L Weintraub; Scott A Barman; David J R Fulton
Journal:  Free Radic Biol Med       Date:  2016-08-03       Impact factor: 7.376

2.  Differential Activation of P-TEFb Complexes in the Development of Cardiomyocyte Hypertrophy following Activation of Distinct G Protein-Coupled Receptors.

Authors:  Ryan D Martin; Yalin Sun; Sarah MacKinnon; Luca Cuccia; Viviane Pagé; Terence E Hébert; Jason C Tanny
Journal:  Mol Cell Biol       Date:  2020-06-29       Impact factor: 4.272

3.  Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension.

Authors:  Eva Nozik-Grayck; Crystal Woods; Robert S Stearman; Sujatha Venkataraman; Bradley S Ferguson; Kalin Swain; Russell P Bowler; Mark W Geraci; Kaori Ihida-Stansbury; Kurt R Stenmark; Timothy A McKinsey; Frederick E Domann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-05-27       Impact factor: 5.464

4.  Epigenetic Reader Bromodomain Containing Protein 2 Facilitates Pathological Cardiac Hypertrophy via Regulating the Expression of Citrate Cycle Genes.

Authors:  Zhirong Lin; Zhenzhen Li; Zhen Guo; Yanjun Cao; Jingyan Li; Peiqing Liu; Zhuoming Li
Journal:  Front Pharmacol       Date:  2022-05-25       Impact factor: 5.988

5.  Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA.

Authors:  Matthew S Stratton; Charles Y Lin; Priti Anand; Philip D Tatman; Bradley S Ferguson; Sean T Wickers; Amrut V Ambardekar; Carmen C Sucharov; James E Bradner; Saptarsi M Haldar; Timothy A McKinsey
Journal:  Cell Rep       Date:  2016-07-14       Impact factor: 9.423

6.  Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation.

Authors:  Clovis Chabert; Saadi Khochbin; Sophie Rousseaux; Sylvie Veyrenc; Rebecca Furze; Nicholas Smithers; Rab K Prinjha; Uwe Schlattner; Christophe Pison; Hervé Dubouchaud
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

7.  BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling.

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

8.  Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension.

Authors:  Sharon Mumby; Natalia Gambaryan; Chao Meng; Frederic Perros; Marc Humbert; S John Wort; Ian M Adcock
Journal:  Respirology       Date:  2016-08-18       Impact factor: 6.175

Review 9.  Epigenetic assays for chemical biology and drug discovery.

Authors:  Sheraz Gul
Journal:  Clin Epigenetics       Date:  2017-04-21       Impact factor: 6.551

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.